Welcome to our dedicated page for MGEN news (Ticker: MGEN), a resource for investors and traders seeking the latest updates and insights on MGEN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MGEN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MGEN's position in the market.
miRagen Therapeutics (NASDAQ: MGEN) will announce its Q2 2020 financial results after market close on August 5, 2020. A conference call will follow at 4:30 p.m. ET, accessible via phone and webcast. miRagen specializes in RNA-targeted therapies, focusing on microRNAs to address significant medical needs. Its clinical candidates include cobomarsen, remlarsen, and MRG-110, aimed at treating various diseases such as blood cancers and heart failure. For more details, visit their investor website.
miRagen Therapeutics, Inc. (NASDAQ: MGEN) has regained compliance with Nasdaq's minimum bid price requirement as of July 1, 2020. The company was initially notified on October 28, 2019, that it failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. Compliance was achieved by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive trading days, with June 30, 2020 marking this achievement.
miRagen Therapeutics (NASDAQ: MGEN) announced promising preclinical data for MRG-229, a miR-29 mimic targeting Idiopathic Pulmonary Fibrosis (IPF). The candidate showed significant anti-fibrotic activity and safety in animal models, reversing pathological gene expression and reducing fibrosis. Preclinical studies indicated no toxicity at high doses. The company believes MRG-229 could be a differentiated treatment for IPF. A conference call on June 23, 2020, will further discuss the unmet needs in IPF and MRG-229's development.
miRagen Therapeutics (NASDAQ: MGEN) has appointed Lee Rauch as Chief Operating Officer, effective immediately. Rauch, a seasoned executive with over 25 years of biotech experience, will oversee business development, investor relations, and corporate communications. Her track record includes leadership roles at Global Blood Therapeutics and other companies. The executive team believes her expertise will enhance miRagen's position in advancing RNA-targeted therapies, including candidates targeting various cancers and cardiac diseases, potentially increasing shareholder value.
miRagen Therapeutics (NASDAQ: MGEN) is set to host a key opinion leaders (KOL) call on June 23, 2020, at 11 a.m. ET, focusing on idiopathic pulmonary fibrosis (IPF). The call will present new preclinical safety and efficacy data on MRG-229, a treatment targeting the low miR-29 levels in IPF. KOLs Dr. Fernando Martinez, Dr. Naftali Kaminski, and Teresa Barnes will share insights into the urgent medical needs in IPF management and address audience queries. MRG-229's development was supported by NIH/NHLBI funding, reflecting its potential significance in combating fibrotic diseases.
miRagen Therapeutics reported operational highlights and financial results for Q1 2020, showcasing a net loss of $8.0 million or $0.18 per share, an improvement from $11.6 million in Q1 2019. Cash and equivalents rose to $36.1 million. The company's COVID-19 impact is notable, particularly affecting the SOLAR trial, leading to delays in patient monitoring and dosing. Positive data for cobomarsen in Adult T-Cell Leukemia/Lymphoma was presented, with an FDA meeting planned in Q2 2020 for an expedited development path. Preclinical studies for MRG-229 are ongoing, bolstered by NIH funding.